{"id":2918,"date":"2020-12-23T12:21:40","date_gmt":"2020-12-23T20:21:40","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=2918"},"modified":"2020-12-24T12:22:48","modified_gmt":"2020-12-24T20:22:48","slug":"evaluating-the-efficacy-of-covid-19-vaccines","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/12\/23\/evaluating-the-efficacy-of-covid-19-vaccines\/","title":{"rendered":"Evaluating the Efficacy of COVID-19 Vaccines"},"content":{"rendered":"<p>Using dual or triple primary endpoints that include SARS-CoV-2 infection, symptomatic infection and severe COVID-19 could speed up characterization and licensure of vaccines for SARS-CoV-2, according to models of placebo controlled-vaccine trials. The authors suggest that dual or triple primary endpoints could speed up the discovery, characterization, and licensure of effective vaccines by creating data that would allow for more rapid interim evaluations and more precise confidence intervals.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><i>Lin et al. (Dec 19, 2020). Evaluating the Efficacy of COVID-19 Vaccines. Clinical Infectious Diseases. <\/i><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciaa1863\">https:\/\/doi.org\/10.1093\/cid\/ciaa1863<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Using dual or triple primary endpoints that include SARS-CoV-2 infection, symptomatic infection and severe COVID-19 could speed up characterization and licensure of vaccines for SARS-CoV-2, according to models of placebo controlled-vaccine trials. The authors suggest that dual or triple primary endpoints could speed up the discovery, characterization, and licensure of effective vaccines by creating data&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/12\/23\/evaluating-the-efficacy-of-covid-19-vaccines\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[25,75,76,33],"topic":[31],"class_list":["post-2918","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-candidate","tag-report","tag-summarize","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=2918"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2918\/revisions"}],"predecessor-version":[{"id":2919,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2918\/revisions\/2919"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=2918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=2918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=2918"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=2918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}